6-氯-N1-甲基苯-1,2-二胺 | 102074-47-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 6-氯-N1-甲基苯-1,2-二胺
• 英文名称: 6-chloro-N¹-methylbenzene-1,2-diamine
• 英文别名: 6-Chloro-N1-methylbenzene-1,2-diamine；3-chloro-2-N-methylbenzene-1,2-diamine
• CAS: 102074-47-5
• 化学式: C₇H₉ClN₂
• mdl: MFCD10694367
• 分子量: 156.615
• InChiKey: VDDRAMKPNRSSMG-UHFFFAOYSA-N

物化性质

• 沸点：
  286.1±25.0 °C(Predicted)
• 密度：
  1.272±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2921590090

反应信息

• 作为反应物：
  描述：

  6-氯-N1-甲基苯-1,2-二胺 在 copper diacetate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 6-chloro-5-methyl-1-phenyl-1,5-dihydro-2H-benzo[b][1,4]diazepine-2,4(3H)-dione
  参考文献：
  名称：

  Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly

  摘要：

  The discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly is described. Synthesis of analogs of the 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione hit established structure-activity relationships. Replacement of the enamine functionality of the hit series with either an imidazole or a pyrazole ring led to compounds that inhibited both capsid assembly and reverse transcriptase. Optimization of the bicyclic benzodiazepine scaffold to include a 3-phenyl substituent led to lead compound 48, a pure capsid assembly inhibitor with improved antiviral activity. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.131
• 作为产物：
  描述：

  2,3-二氯硝基苯 在 氢气 、 铜 作用下， 以 乙醇 、 水 为溶剂， 20.0~100.0 ℃ 、101.33 kPa 条件下， 反应 11.0h， 生成 6-氯-N1-甲基苯-1,2-二胺
  参考文献：
  名称：

  Discovery of 2-iminobenzimidazoles as potent hepatitis C virus inhibitors with a novel mechanism of action

  摘要：

  In this report we describe 2-iminobenzimidazole (IBI) analogs, identified during the course of a phenotypic high-throughput screening campaign, as novel hepatitis C virus (HCV) inhibitors. A series of IBI derivatives was synthesized and evaluated for their inhibitory activity against infectious HCV. Among the IBIs derivatives studied in this work, we identified promising compounds with high antiviral efficacy, high selectivity index and good microsomal stability. Noteworthy, the IBI series exhibited inhibitory activity on early and late steps of the viral cycle, but not in the HCV replicon system demonstrating a mechanism of action distinct from clinical-stage and approved anti-HCV drugs. Overall, our results suggest that IBIs are predestinated for further exploration as lead compounds for novel HCV interventions. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.03.030

文献信息

• Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
  申请人：Egle Ian

  公开号：US20090192169A1

  公开（公告）日：2009-07-30

  Compounds of Formula I: wherein A, B, D, L, R 1 , R 2 , R 3 , R 4 , m, and n are as defined for Formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

  式I的化合物： 其中A、B、D、L、R1、R2、R3、R4、m和n的定义如描述中所定义。本发明还涉及制备这些化合物的方法，以及用于制备的新中间体，含有这些化合物的药物组合物，以及这些化合物在治疗中的应用。
• Discovery of selective fragment-sized immunoproteasome inhibitors
  作者：Levente Kollár、Martina Gobec、Bence Szilágyi、Matic Proj、Damijan Knez、Péter Ábrányi-Balogh、László Petri、Tímea Imre、Dávid Bajusz、György G. Ferenczy、Stanislav Gobec、György M. Keserű、Izidor Sosič

  DOI：10.1016/j.ejmech.2021.113455

  日期：2021.7

  benzoXazole-2(3H)-thiones) as inhibitors of the chymotrypsin-like (β5i) subunit of the immunoproteasome. A subsequent structure-activity relationship study provided us with an insight regarding growing vectors. Binding to the β5i subunit was shown and selectivity against the β5 subunit of the constitutive proteasome was determined. Thorough characterization of these compounds suggested that they inhibit the immunoproteasome

  蛋白酶体有助于维持蛋白质稳态，其抑制作用对某些类型的癌症和自身免疫疾病有益。然而，对健康细胞中蛋白酶体的抑制会导致不希望有的副作用，并且已经做出重大努力来鉴定对免疫蛋白酶体具有特异性的抑制剂，特别是用于治疗表现出该蛋白酶体同种型的水平和活性增加的疾病。在这里，我们报告了我们为发现人类免疫蛋白酶体的片段大小抑制剂所做的努力。内部结构多样化片段文库的筛选导致苯并[ d ]恶唑-2(3 H )-硫酮、苯并[ d ]噻唑-2(3 H )-硫酮、苯并[ d ]恶唑-2(3 H )-硫酮的鉴定]咪唑-2(3 H )-硫酮和 1-甲基苯并[ d ]咪唑-2(3 H )-硫酮（通用术语苯并恶唑-2（3 H）)-硫酮) 作为免疫蛋白酶体胰凝乳蛋白酶样 (β5i) 亚基的抑制剂。随后的构效关系研究为我们提供了有关生长载体的见解。显示了与 β5i 亚基的结合，并确定了对组成型蛋白酶体的 β5 亚基的选择性。对这些化合物的彻底表征表明，它们通过与
• Spiroconjugated Tetraaminospirenes as Donors in Color‐Tunable Charge‐Transfer Emitters with Donor‐Acceptor Structure
  作者：David C. Grenz、Daniel Rose、Jan S. Wössner、Jennifer Wilbuer、Florin Adler、Mathias Hermann、Chin‐Yiu Chan、Chihaya Adachi、Birgit Esser

  DOI：10.1002/chem.202104150

  日期：2022.1.27

  Emitters go spiro: Using spiroconjugated tetraamines as a novel type of donor and a range of different acceptors in three different modes of connection, 12 donor-acceptor compounds are synthesized. Their twisted structures lead to a spatial separation of the HOMOs and LUMOs. Photophysical measurements show tunable emission colors for these donor-acceptor compounds, and photoluminescence quantum yields

  螺螺发射体：使用螺共轭四胺作为新型供体和一系列不同的受体以三种不同的连接方式，合成了 12 种供体-受体化合物。它们的扭曲结构导致 HOMO 和 LUMO 的空间分离。光物理测量显示这些供体-受体化合物的发射颜色可调，并且在溶液中获得高达 99% 的光致发光量子产率。
• NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS
  申请人：Bessis Anne-Sophie

  公开号：US20090124625A1

  公开（公告）日：2009-05-14

  The present invention relates to novel compounds of formula (I) wherein W, n, X and W′ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.

  本发明涉及化合物的新型配方（I），其中W，n，X和W′在说明书中定义；发明的化合物是代谢型谷氨酸受体-亚型5（“mGluR5”）的调节剂，可用于治疗中枢神经系统疾病以及其他受mGluR5受体调节的疾病。
• METHOD FOR PRODUCING BIARYL COMPOUND
  申请人：Sato Koichi

  公开号：US20100087680A1

  公开（公告）日：2010-04-08

  A method for producing a biaryl compound, comprising reacting an aromatic organic compound with at least one compound selected from the group consisting of aromatic organoboron compounds and boroxine compounds, in the presence of a zero-valent nickel catalyst, phosphine ligand and base.

  一种制备双芳基化合物的方法，包括在零价镍催化剂、膦配体和碱的存在下，将芳香有机化合物与选自芳香基有机硼化合物和硼氧化物化合物组的至少一种化合物反应。